通讯作者: 卢雪玲, 1204538272@qq.com

DOI：10.12201/bmr.202608.00002

Advances in Glucagon-Like Peptide-1 Receptor Agonists for Metabolic Treatment of Polycystic Ovary Syndrome

• 摘要：多囊卵巢综合征(polycystic ovary syndrome,PCOS)是育龄期女性常见的生殖内分泌疾病,其发病不仅与排卵障碍和高雄激素血症有关,还伴随肥胖、胰岛素抵抗、糖脂代谢异常及慢性低度炎症等代谢紊乱。近年来,国际专家提出将其重新命名为多内分泌代谢卵巢综合征(polyendocrine metabolic ovarian syndrome,PMOS),进一步强调代谢异常在疾病发生发展中的核心地位。胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1RA)因具有减重、改善胰岛素抵抗和调节代谢等作用,逐渐成为PCOS治疗研究的热点。本文综述GLP-1RA在PCOS中的药理基础、作用机制及临床应用，重点总结其对体重、胰岛素抵抗、糖脂代谢、生殖内分泌及生育结局的影响，并分析联合治疗、安全性、局限性及新型肠促胰素药物前景，为PCOS个体化代谢管理提供参考。

  关键词： 多囊卵巢综合征；胰高糖素样肽-1受体激动剂；胰岛素抵抗；肥胖；代谢治疗; ; ; ; 

   

  Abstract: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. In addition to reproductive dysfunction characterized by hyperandrogenism and ovulatory disorders, PCOS is frequently accompanied by obesity, insulin resistance, dyslipidemia, chronic low-grade inflammation, and an increased risk of long-term cardiometabolic complications. Recently, an international consensus proposed renaming PCOS as polyendocrine metabolic ovarian syndrome (PMOS), highlighting the central role of metabolic abnormalities in its pathogenesis and clinical management. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for the treatment of type2 diabetes and obesity, have attracted increasing attention in PCOS because of their beneficial effects on body weight reduction, insulin sensitivity, and metabolic regulation. This review summarizes recent advances in the pharmacological basis, mechanisms of action, and clinical applications of GLP-1RAs in PCOS. Current evidence indicates that GLP-1RAs can improve body weight, insulin resistance, glucose and lipid metabolism, and hyperandrogenism, and may contribute to improvements in menstrual regularity, ovulatory function, and reproductive outcomes. Emerging studies also suggest potential roles of GLP-1RAs in modulating inflammation, gut microbiota, oxidative stress, and ovarian microenvironment. This review covers the pharmacology, mechanisms, and clinical use of GLP-1RAs in PCOS, emphasizing impacts on weight, insulin resistance, metabolism, reproductive hormones, and fertility, while also addressing combination strategies, safety, current limitations, and emerging incretin therapies to support personalized PCOS management.

  Key words: Polycystic Ovary Syndrome; Glucagon-Like Peptide-1 Receptor Agonists; Insulin Resistance; Obesity; Metabolic Therapy

  提交时间：2026-08-03

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 高春柳, 张晗, 褚梦圆, 许凯凯, 项馨, 闫颖. Isthmin1蛋白在多囊卵巢综合征中作用机制的进展. 2024. doi: 10.12201/bmr.202411.00004

  符月婷, 褚烔, 肖汐, 王佩娟. 多囊卵巢综合征的代谢核心病理机制及治疗的研究进展. 2025. doi: 10.12201/bmr.202512.00007

  杨颖榕, 刘宏. GLP-1受体激动剂减轻心肌缺血再灌注损伤的研究进展. 2026. doi: 10.12201/bmr.202605.00028

  聂心雨, 刘凌燕. 多囊卵巢综合征中的铁死亡和内质网应激及相关潜在治疗靶点. 2025. doi: 10.12201/bmr.202507.00042

  胡芳芩, 沈清. 心肾代谢综合征的新型药物治疗进展. 2026. doi: 10.12201/bmr.202604.00070

  孟黎明, 李晓, 姚红梅. 合并多囊卵巢综合征的卵巢类固醇细胞瘤1例. 2025. doi: 10.12201/bmr.202505.00034

  陈盈. 玛仕度肽在肥胖人群中的应用研究进展. 2026. doi: 10.12201/bmr.202604.00089

  郑海娟, 牛晓珊. CCR与代谢综合征及其相关疾病的研究进展. 2025. doi: 10.12201/bmr.202501.00048

  郑洁, 张真稳. SGLT2抑制剂对代谢综合征各组分的影响. 2025. doi: 10.12201/bmr.202503.00002

  陈云秀, 赫晓媛, 宁美. 胰岛素抵抗与结直肠癌发生发展关系及干预措施的研究进展. 2026. doi: 10.12201/bmr.202601.00062

• 序号	提交日期	编号	操作
  1	2026-07-06	10.12201/bmr.202608.00002V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论